New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
19:59 EDTRHHBYRoche ovarian cancer drug Avastin denied U.K. regulator support, Bloomberg says
Roche's (RHHBY) Avastin, an anti-tumor drug, did not receive the support of the U.K.'s National Institute for Health and Clinical Excellence, with the Institute citing the recommended dose as making it difficult to make clear how effective the medication is, according to a Bloomberg report that cites an e-mailed statement from the Institute. Reference Link
News For RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
08:33 EDTRHHBYHalozyme and Ventana enter into global agreement to develop companion diagnostic
Halozyme (HALO) and Ventana Medical Systems, a member of the Roche (RHHBY), announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20. The Ventana assay will be used to identify high levels of hyaluronan. HA is a glycosaminoglycan that can accumulate around cancer cells. Halozyme has announced plans for rollout of a global phase 3 clinical study in 2016 targeting metastatic pancreatic cancer patients with high HA levels using its PEGPH20 in combination with ABRAXANE and gemcitabine. Under the agreement, Ventana will develop an in vitro diagnostic, under design control, using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval in the United States, Europe and other countries. The financial terms of the agreement were not disclosed.
May 22, 2015
10:52 EDTRHHBYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTRHHBYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 18, 2015
16:07 EDTRHHBYIllumina files new patent infringement suit against Roche unit
Subscribe for More Information
10:01 EDTRHHBYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: A10 Networks (ATEN) upgraded to Overweight from Sector Weight at Pacific Crest... Cal-Maine Foods (CALM) upgraded to Overweight from Equal Weight at Stephens... ChemoCentryx (CCXI) upgraded to Overweight from Neutral at JPMorgan... Cheniere Energy Partners LP (CQP) upgraded to Buy from Neutral at Goldman... Chicago Bridge & Iron (CBI) upgraded to Neutral from Sell at Goldman... Continental Resources (CLR) upgraded to Buy from Neutral at Goldman... Ctrip.com (CTRP) upgraded to Overweight from Neutral at JPMorgan... Emerge Energy (EMES) upgraded to Buy from Neutral at Goldman... FEMSA (FMX) upgraded to Overweight from Equal Weight at Morgan Stanley... GoPro (GPRO) upgraded to Perform from Underperform at Oppenheimer... Holly Energy (HEP) upgraded to Buy from Neutral at Goldman... JP Energy (JPEP) upgraded on better visibility on volumes at RBC Capital... Laredo Petroleum (LPI) upgraded to Neutral from Sell at Goldman... Malvern Bancorp (MLVF) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Goldman... Norsk Hydro (NHYDY) upgraded to Overweight from Neutral at JPMorgan... Owens-Illinois (OI) upgraded to Neutral from Underperform at BofA/Merrill... Penn National (PENN) upgraded to Buy from Neutral at Goldman... Roche (RHHBY) upgraded to Buy from Neutral at UBS... Schnitzer Steel (SCHN) upgraded on stabilizing headwinds at KeyBanc... Seventy Seven Energy (SSE) upgraded to Buy from Hold at Jefferies... Toll Brothers (TOL) upgraded to Neutral from Underperform at Sterne Agee CRT... United Therapeutics (UTHR) upgraded to Buy from Neutral at BTIG... Volvo (VOLVY) upgraded to Neutral from Underweight at JPMorgan... Zayo Group (ZAYO) upgraded to Buy from Neutral at Goldman.
09:23 EDTRHHBYRoche upgraded to Buy from Neutral at UBS
Subscribe for More Information
May 14, 2015
09:22 EDTRHHBYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use